Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Maviret

Maviret 100 mg/40 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–8

HOS-139037 · Präparat HOS-098268

6 ANTIMYCOBACTERIALS Rifampicin ↑ glecaprevir 6.52 8.55 Co-administration 600 mg single (5.06, 8.41) (7.01, -- is contraindicated dose 10.4) (see section 4.3). ↔ ↔ ↔ -- (Inhibition of pibrentasvir OATP1B1/3) Rifampicin ↓ glecaprevir 0.14 0.12 -- 600 mg once (0.11, 0.19) (0.09, dailya 0.15) ↓ pibrentasvir 0.17 0.13 -- (Induction of P- (0.14, 0.20) (0.11, gp/BCRP/CYP3A 0.15) ) ETHINYL-OESTRADIOL-CONTAINING PRODUCTS Ethinyloestradiol ↑ EE 1.31 1.28 1.38 Co-administration (EE)/Norgestimate (1.24, 1.38) (1.23, (1.25, 1.52) of Maviret with 35 µg/250 µg once 1.32) ethinyloestradiol- daily ↑ ↔ 1.44 1.45 containing norelgestromi (1.34, (1.33, 1.58) products is n 1.54) contraindicated ↑ norgestrel 1.54 1.63 1.75 due to the risk of (1.34, 1.76) (1.50, (1.62, 1.89) ALT elevations 1.76) (see section 4.3). EE/Levonorgestrel ↑ EE 1.30 1.40 1.56 No dose 20 µg/100 µg once (1.18, 1.44) (1.33, (1.41, 1.72) adjustment is daily 1.48) required with ↑ norgestrel 1.37 1.68 1.77 levonorgestrel, (1.23, 1.52) (1.57, (1.58, 1.98) norethidrone or 1.80) norgestimate as contraceptive progestagen. HERBAL PRODUCTS St. John’s wort Not studied. Co-administration (Hypericum Expected: ↓ glecaprevir and ↓ pibrentasvir may lead to perforatum) reduced therapeutic effect (Induction of P- of Maviret and is gp/CYP3A) contraindicated (see section 4.3). HIV-ANTIVIRAL AGENTS Atazanavir + ↑ glecaprevir ≥4.06 ≥6.53 ≥14.3 Co-administration ritonavir (3.15, 5.23) (5.24, (9.85, 20.7) with atazanavir is 300/100 mg once 8.14) contraindicated dailyb ↑ pibrentasvir ≥1.29 ≥1.64 ≥2.29 due to the risk of (1.15, 1.45) (1.48, (1.95, 2.68) ALT elevations 1.82) (see section 4.3). Darunavir + ↑ glecaprevir 3.09 4.97 8.24 Co-administration ritonavir (2.26, 4.20) (3.62, (4.40, 15.4) with darunavir is 800/100 mg once 6.84) not daily ↔ ↔ ↔ 1.66 recommended. pibrentasvir (1.25, 2.21) Efavirenz/emtricit ↑ tenofovir ↔ 1.29 1.38 Co-administration abine/tenofovir (1.23, (1.31, 1.46) with efavirenz disoproxil 1.35) may lead to fumarate The effect of efavirenz/emtricitabine/tenofovir disoproxil reduced fumarate on glecaprevir and pibrentasvir was not directly therapeutic effect 7 600/200/300 mg quantified within this study, but glecaprevir and of Maviret and is once daily pibrentasvir exposures were significantly lower than not historical controls. recommended. No clinically significant interactions are expected with tenofovir disoproxil fumarate. Elvitegravir/cobici ↔ tenofovir ↔ ↔ ↔ No dose stat/emtricitabine/ ↑ glecaprevir 2.50 3.05 4.58 adjustment is tenofovir (2.08, 3.00) (2.55, (3.15, 6.65) required. alafenamide 3.64) ↑ pibrentasvir ↔ 1.57 1.89 (P-gp, BCRP, and (1.39, (1.63, 2.19) OATP inhibition 1.76) by cobicistat, OATP inhibition by elvitegravir) Lopinavir/ritonavi ↑ glecaprevir 2.55 4.38 Co-administration 18.6 r 400/100 mg (1.84, 3.52) (3.02, is not (10.4, 33.5) twice daily 6.36) recommended. ↑ pibrentasvir 1.40 2.46 5.24 (1.17, 1.67) (2.07, (4.18, 6.58) 2.92) Raltegravir ↑ raltegravir 1.34 1.47 2.64 No dose 400 mg twice (0.89, 1.98) (1.15, (1.42, 4.91) adjustment is daily 1.87) required.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) lopinavir (HOS-086269) atazanavir (HOS-086180) norgestimate (HOS-110544) levonorgestrel (HOS-089677) cobicistat (HOS-088111) tenofovir disoproxil (HOS-108843) lead (HOS-085592) fumarate (HOS-108845) darunavir (HOS-086181) efavirenz (HOS-087947) raltegravir (HOS-086187) ritonavir (HOS-084521) elvitegravir (HOS-088110) emtricitabine (HOS-085840) norgestrel (HOS-090613)